The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 13, 2021

Filed:

May. 21, 2014
Applicants:

Emily Carla Dykhuizen, West Lafayette, IN (US);

Diana Clare Hargreaves, San Mateo, CA (US);

Cigall Kadoch, Tiburon, CA (US);

Gerald R. Crabtree, Woodside, CA (US);

Inventors:

Emily Carla Dykhuizen, West Lafayette, IN (US);

Diana Clare Hargreaves, San Mateo, CA (US);

Cigall Kadoch, Tiburon, CA (US);

Gerald R. Crabtree, Woodside, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); A61K 31/352 (2006.01); A61K 31/704 (2006.01); A61K 31/496 (2006.01); C12Q 1/6886 (2018.01); A61K 31/475 (2006.01); A61K 31/473 (2006.01); A61K 31/05 (2006.01); A61K 31/136 (2006.01); A61K 31/353 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57496 (2013.01); A61K 31/05 (2013.01); A61K 31/136 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/473 (2013.01); A61K 31/475 (2013.01); A61K 31/496 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/914 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.


Find Patent Forward Citations

Loading…